RE:RE:RE:What I'd like to know is ...I think you need to go back and consult the record, digitel. Then you need to apply some logic to your assumptions and expectations.
Independent studies? Bioasis conducts its own studies with
CROs (Contract Research Organizations). Bioasis needs accurate data about xB3-001. They expect to get that from studies designed by Bioasis and its CRO collaborators, and then conducted by the CROs. CROs that don't produce accurate data won't be in the CRO business for very long. Is there any need for independent studies before clinical trials begin? Do we need three blind mice studies?
NHPs with cancer? You mean target engagement studies? So, how do you do that before delivery of fusion proteins? In my piece on
target engagement I pointed out that a lot of studies are needed before target engagement can be done.
Didn't Bioasis sign an
agreement with WuXi in May? Would target engagement take place without those fusion proteins?
Didn't Bioasis state then that, "
Bioasis will draw on WuXi Biologics’ expertise in developing complex biologic molecules for production of xB3-001 to support analytical development, formulation and IND-enabling in vivo studies."? (Think maybe that might be target engagement?)
Those monkeys were naive monkeys, no disease, in them. No targets. That comes later. But there's lots to learn about the behaviour of xB3-001 in animal studies and we got an indication of that in yesterday's press release.
And it's wise to remember that data and other study results are seldomly released to the public and are generally available only to potential licencees and partners after they sign non-disclosure agreements. (Data room?)
We all would like to know everything today, digitel. More to the point, we'd all love to have our money right now and run away with it. Bioasis is working on that.
jdstox